Related Experiment Video

Updated: May 9, 2026

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma

Olga K Mirzoeva1, Eric A Collisson, Peter M Schaefer

  • 1Corresponding Author: W. Michael Korn, UCSF Divisions of Gastroenterology and Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, 2340 Sutter St., Box 1387, San Francisco, CA 94115. Michael.Korn@ucsf.edu.

Molecular Cancer Therapeutics
|August 7, 2013
PubMed

Insights

Targeting KRAS-mutated pancreatic cancer (PDA) with MEK and EGFR inhibitors shows promise. This combination therapy induces apoptosis in epithelial PDA subtypes, offering a personalized treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • KRAS oncogene mutations are prevalent in pancreatic ductal adenocarcinoma (PDA).
  • The KRAS protein is considered undruggable, necessitating exploration of downstream therapeutic targets.
  • Targeting signaling pathways downstream of KRAS is a rational strategy for PDA treatment.

Purpose of the Study:

  • To investigate the effects of MAP-ERK kinase (MEK) inhibition in PDA cell lines.
  • To evaluate the efficacy of combining MEK and epidermal growth factor receptor (EGFR) inhibitors.
  • To identify biomarkers predicting response to combination therapy in different PDA subtypes.

Main Methods:

  • Utilized a large panel of pancreatic ductal adenocarcinoma cell lines.
  • Administered MEK inhibitors and assessed downstream signaling.
  • Combined MEK and EGFR inhibitors and evaluated synergistic apoptosis induction.
  • Performed RNA expression analysis to identify predictive biomarkers.

Main Results:

  • MEK inhibition activated phosphoinositide 3-kinase in an EGFR-dependent manner.
  • Combinations of MEK and EGFR inhibitors synergistically induced apoptosis in epithelial PDA subtypes.
  • Epithelial PDA subtypes showed susceptibility predicted by E-cadherin, HER3, and miR200 family microRNAs.
  • Mesenchymal PDA subtypes exhibited resistance, associated with ZEB1 expression.
  • HER3 knockdown sensitized epithelial cells, while ZEB1 knockdown sensitized mesenchymal cells to the combination therapy.

Conclusions:

  • Combination therapy with MEK and EGFR inhibitors offers a subtype-specific approach for pancreatic cancer.
  • Biomarkers such as E-cadherin, HER3, miR200 family, and ZEB1 can predict treatment response.
  • This research suggests a personalized therapeutic strategy for pancreatic cancer based on subtype and molecular markers.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...